Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Abt-724. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.81 |
| ▸ | DRD4 | P21917 | 17/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.80 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.80 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.80 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt-724 SCHEMBL4807361 | 1.00 | DRD4 (0.81) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL1448486 | 0.90 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL29406160 | 0.90 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL29634880 | 0.89 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL6316908 | 0.89 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL6551097 | 0.89 | DRD4 (0.80) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL6317285 | 0.87 | DRD4 (0.85) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL6325676 | 0.87 | DRD4 (0.85) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL3435012 | 0.79 | DRD4 (0.71) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6096279 | 0.78 | DRD4 (0.76) | DRD4DRD2KDM4EALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373220-B1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LAB (US) | 2007-05-30 | — | — | EP | claimed |
| US-10098875-B2 | Method of treatment for mental disorders | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-10-16 | — | — | US | disclosed |
| US-20160129000-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-7351828-B2 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1373220-B1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LAB (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7022728-B2 | Benzimidazoles that are useful in treating male sexual dysfunction | ABBOTT LABORATORIES (US) | 2006-04-04 | — | — | US | disclosed |
| US-6960589-B2 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1483258-A1 | BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-07-01 | — | — | US | disclosed |
| US-20040110766-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-06-10 | — | — | US | disclosed |
| EP-1373220-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003076431-A1 | BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2003-08-28 | — | — | US | disclosed |
| US-20030008878-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABOTT LABORATORIES | 2003-01-09 | — | — | US | disclosed |
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| WO-2002088093-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD2 2231/4885DRD4 2278/4885KDM4E 2948/4885 |
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD2 2231/4885DRD4 2278/4885KDM4E 2948/4885 |
| US-20030008878-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD2 2231/4885DRD4 2278/4885KDM4E 2948/4885 |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD2 2231/4885DRD4 2278/4885KDM4E 2948/4885 |
| US-10098875-B2 | Method of treatment for mental disorders | DRD4, HTR4, SLC6A3 | DRD2 6/4885DRD4 1/4885KDM4E 826/4885 |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD2 2231/4885DRD4 2278/4885KDM4E 2948/4885 |
| US-20160129000-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD2 6/4885DRD4 1/4885KDM4E 826/4885 |
| US-20040110766-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD2 2231/4885DRD4 2278/4885KDM4E 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.